Redeye's view of Genovis Q2 report is balanced, sales were largely in line but profitability was sof...
Redeye provides an initial take on the Q2 2025 report from Scandinavian ChemoTech.
Alisa Bank’s H1 financials were as expected weak but still slightly below our estimates.
Raute’s EUR 43.8m Q2 top line came in clearly below our estimate, yet the EUR 6.
Marimekko reports its Q2 figures on 14th of August.
Market conditions remain unfavourable for Aurdel Septon divestment carries largest impact on estimat...
Net sales were below our expectations and adjusted EBITDA was above for Q2.
Redeye comments on Alzinova’s announcement of having submitted an IND application and a Fast Track D...
Group net sales was EUR 29.5m in Q2 (Nordea EUR 30.
Vi inleder bevakning på mResell, en ledande svensk aktör inom re-commerce som specialiserar sig på r...
Negative trend sustained, but there are a few growth options in H2 We cut adj.
Redeye comments on q.beyond’s Q2 report showing a slightly more substantial improvement in EBITDA an...
Redeye presents its preview for Paxman’s Q2 2025 report, due on August 20.
Redeye notes a soft Q2 on both sales and EBIT, and we expect a negative share price reaction today o...
Redeye negatively views Surgical Science’s profit warning for Q2 2025.
SRV's net sales in Q2 amounted to EUR 168.7m, slightly below our estimate of EUR 174.
Suominen faced another setback on its earnings recovery path as US volumes were missing big time.
DT’s Q2 earnings were softer than estimated and disappointingly Q3 results too are about to decline,...
Redeye updates on G5 after weaker-than-expected Q2-results which have resulted in lowered estimates.
